Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of “Buy” by Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have been assigned a consensus recommendation of “Buy” from the seventeen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, fourteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $33.79.

DNLI has been the topic of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $31.00 price objective on the stock. Wedbush cut their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group cut their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. William Blair upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Thursday, April 24th. Finally, B. Riley restated a “buy” rating and issued a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th.

Institutional Investors Weigh In On Denali Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in Denali Therapeutics by 0.3% in the 4th quarter. Rhumbline Advisers now owns 190,390 shares of the company’s stock valued at $3,880,000 after buying an additional 497 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after buying an additional 885 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its position in shares of Denali Therapeutics by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company’s stock valued at $548,000 after buying an additional 1,058 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after buying an additional 1,516 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Denali Therapeutics by 277.0% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after buying an additional 1,551 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $13.96 on Thursday. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -5.06 and a beta of 1.49. The stock’s 50-day moving average is $14.15 and its 200 day moving average is $19.83. Denali Therapeutics has a one year low of $10.57 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same quarter last year, the company earned ($0.68) earnings per share. On average, sell-side analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.